Acute myeloid leukemia is a heterogeneous disease. Standard treatments may be applied to biologically distinct subgroups, resulting in different treatment outcomes. The concept of risk-adapted therapy allows for recognition of this biologic diversity by incorporating key biologic features, such as cytogenetic and molecular markers, when formulating treatment regimens and investigating emerging targeted therapies based on disease characteristics. (JNCCN 2008;6:995-1002) 
Learning objectives
Upon completion of this activity, participants will be able to:
• Identify the demographic and disease factors associated with a poor prognosis in acute myeloid leukemia (AML) • List the cytogenetic markers associated with a poor prognosis in AML • List the molecular markers associated with a good prognosis in AML • Describe strategies for the use of molecular and cytogenetic markers in the treatment of patients with AML
Although acute myeloid leukemia (AML) has been the focus of significant laboratory and clinical investigation, it remains difficult to treat, perhaps partly because of the fundamental nature of the disorder, which requires substantial institutional resources to adequately deal with the complications of bone marrow failure and sustain patients through periods of intensive therapy. Although supportive measures have generally improved within the past 20 years, the drugs that form the backbone of standard AML chemotherapy remain essentially unchanged.
1
Evolution of Prognostic Markers
The introduction of cytarabine (Ara-C) in the 1960s represented a major advance in therapy, which previously relied primarily on the experience garnered from pediatric acute lymphoblastic leukemia. The recognition that adding an anthracycline could improve clinical outcomes eventually resulted in the formation of the modern "7+3" induction regimen. [2] [3] [4] Although some minor variations have been introduced, this regimen has largely remained standard since the 1980s. Despite a uniform approach, treatment results showed that not all patients had similar outcomes. The first readily apparent demarcation point was age; 3, 4 older patients (> 55-60 years) had inferior outcomes compared with younger cohorts. This caused CALGB to advocate dose attenuation of the anthracycline for an interval to ameliorate toxicity. 4 The morbidity/ mortality associated with therapy was not, however, the only factor responsible for the relatively poor treatment results. Elderly patients were also noted to have a higher degree of drug resistance, leading some investigators to postulate that this form of AML arose from a more primitive hematopoietic progenitor than the forms seen in de novo AML in patients younger than 60 years.
5,6
The beginnings of risk-adapted therapy were based on these early observations of the prognostic importance of age. Treatment regimens began to evolve based on this prognostic factor. The emphasis in treating elderly AML initially centered on limiting toxicity and providing a more tolerable therapy. These trends have continued and are reflected in the interest in low-impact therapies such as tipifarnib or low-dose Ara-C.
Age was not, however, found to be the only significant factor affecting treatment outcomes. As further experience was gained with standard treatment regimens, it became evident that patients who developed a secondary AML after an antecedent hematologic disorder or prior chemotherapy had inferior outcomes compared with age-matched patients with de novo AML.
7
Remission rates were approximately 33% to 50% lower than those seen in de novo disease, and durations were generally shorter. These clinical results underscore the biologic difference between de novo and secondary disease. The presence of an antecedent hematologic disorder was also found to be age-related, because a higher percentage of elderly patients had secondary AML. 8 The recognition that the standard "7+3" induction regimen with dose-attenuated postremission consolidation is essentially inadequate therapy for these patients prompted several investigations, ranging from the introduction of newer chemotherapeutic agents to strategies based on various modifications of stem cell transplantation.
9,10

Importance of Cytogenetics
Ultimately, however, the most important prognostic factor was found to be the biology of the underlying disorder, as reflected by the cytogenetics. Multiple clinical trials have reported the prognostic importance of pretreatment cytogenetics.
11-14 Several large studies have helped categorize chromosomal abnormalities into good-, intermediate-, and poor-risk groups (Table 1) . The Medical Research Council of the United Kingdom reported that this hierarchical system of karyotype classification retained its predictive value across different age groups and in de novo and secondary AML. It was also found to retain prognostic significance across the different treatment modalities of chemotherapy and autologous and allogeneic bone marrow transplantation.
Although several of the larger classification schemas have some minor differences, they are more similar than different. Generally, the poor-risk or © Journal of the National Comprehensive Cancer Network Volume 6 Number 10 November 2008 In contrast, stem cell transplantation in first complete remission (CR) is generally not recommended in patients with good-risk or favorable cytogenetics. Included in this category are those with t(15;17), t(8;21), t(16;16), and inv(16) translocations. Acute promyelocytic leukemia (APL), defined by the t(15;17) translocation, has a distinct biology, and combinations of doseintensive anthracyclines, all-trans-retinoic acid (ATRA), and arsenic trioxide may be curative for most patients.
15
The core-binding factor leukemias [t(8;21), t(16:16), and inv(16)] are so named because the chromosomal translocation results in the fusion of a gene to either the ␣ or ␤ subunit that constitutes the heterodimeric corebinding factor, resulting in the recruitment of histone deacetylase to the promoter. Activity of this enzyme results in inhibition of transcriptional activity from promoters of genes involved in cellular differentiation. These leukemias are exquisitely sensitive to high-dose Ara-C. When patients are treated with dose-intensive regimens, overall survival may be approximately 60%. 16 Patients who have chromosomal abnormalities that do not fit into the other categories are considered to have intermediate-risk disease. The largest group within this category is patients with a normal karyotype, representing approximately 40% to 49% of adults with de novo AML.
12-14 However, unlike the other prognostic groupings, these patients have a broad range of treatment outcomes, prompting a search for other potential prognostic markers that would be useful in defining subgroups and planning treatment strategies.
Emergence of Molecular Markers
The discovery of several molecular markers associated with AML (Table 2) , involving either mutations within specific key genes or changes in the level of expression of specific genes, have been implicated in the process of leukemogenesis and provided the basis for further refining the prognostic models initially established by the cytogenetic data. This field of investigation is rapidly evolving. Some major molecular markers are briefly reviewed here, but several excellent publications provide more extensive discussion. 17, 18 According to a multi-hit model of leukemogenesis originally proposed by Gilliland and Griffin, 19 the molecular abnormalities important in AML may be 1 of 2 functional types: class I abnormalities that result in a proliferative and survival advantage for immature hematopoietic cells, or class II abnormalities that alter hematopoietic differentiation, maturation, and apoptosis. 19 Both changes cooperate to produce the leukemic phenotype. Therefore, they are not random and some class I changes are more likely to be found with certain class II abnormalities.
One of the first reproducible recurrent genetic changes identified was the length or internal tandem duplications (ITD) within the juxtamembrane domain of the FMS-like tyrosine kinase 3 (FLT3) receptor that results in constitutive activation of the enzyme through destabilizing the negative regulatory function of the juxtamembrane domain. This constitutive © Journal of the National Comprehensive Cancer Network Volume 6 Number 10 November 2008 activation results in the abnormal activation of the STAT5 and FOXO transcription factors, up-regulation of the Pim-1 and -2 proto-oncogenes, and downregulation of the CEBP␣ transcription factor that is involved in normal myeloid differentiation. [20] [21] [22] [23] [24] Since this abnormality was identified in the mid1990s, it has been found to be common in the normal cytogenetic group and can be detected in approximately 28% to 33% of these patients. The presence of an ITD has been shown to confer a worse clinical prognosis, and therefore suitable patients with this abnormality usually undergo allogeneic bone marrow transplantation in first remission.
19,25-28 Furthermore, heterogeneity may exist within the FLT3-ITD-positive group, because some individuals are homozygous for the mutated allele, whereas others have one wild-type copy of the allele. Several groups have reported the prognostic significance of the allelic ratio (mutated-to-wild-type), with higher values ultimately having a worse prognosis.
A second mutation in the FLT3 gene has been observed in approximately 5% of patients with AML and involves a point mutation at aspartate 835 within the activation loop of the enzyme. It is analogous to point mutations seen and characterized in multiple other receptor kinases, including KIT, and results in shifting the activation loop of the kinase domain to an open configuration, allowing constitutive kinase activation. The clinical prognosis for this particular mutation is currently a point of controversy, because this mutation may not confer as negative a prognosis as the ITD.
28,29
Further poor prognostic markers have been identified in several other genes. For example, activating mutations in the KIT kinase in the context of a corebinding factor cytogenetic abnormality confers a poor prognosis.
30-32 In addition, length or partial tandem duplication (PTD) involving the mixed lineage leukemia gene (MLL) was the first adverse prognostic marker identified in AML with normal cytogenetics.
33
In normal cytogenetics AML, MLL-PTD affects only one allele, and expression of the second, wild-type, allele is silenced. Distinct from the chimeric fusion proteins involving 11q23 translocations that have been found to retain the DNA binding activity but lack the histone methyltransferase domain, MLL-PTD results from the PTD of exons 5 to 11 encoding an elongated protein that retains the histone H3 lysine 4 methyltransferase activity. This results in increased global DNA methylation and likely silencing of tumor suppressor genes, leading to the development of poor-prognosis disease.
34-36
A recent CALGB study showed that in patients with normal cytogenetics AML, the poor prognostic effect of MLL-PTD can be potentially abated through use of intensive consolidation chemotherapy in first CR, including autologous peripheral stem cell transplantation.
37
Overexpression of other genes, including the survival factor CXCR4, BAALC, MN1, and ERG, as well as WT1 mutations are also believed to confer a poor prognosis.
17, [38] [39] [40] [41] [42] [43] [44] Two class II mutations have been identified that confer a good prognosis in patients with AML who do not also have a FLT3-ITD abnormality. The first is a mutation within exon 12 of the nucleophosmin gene that results in cytoplasmic as opposed to nuclear localization of the protein. [45] [46] [47] [48] [49] This abnormality can be seen in up to 25% of patients with AML. The second is a mutation within the CCAAT/enhancer binding protein ␣ (C/EBP␣). 50, 51 This protein binds DNA through the carboxy-terminal basic region and leucine zipper motif, and can activate transcription by way of 2 amino-terminal transcriptional activation domains. 52 Amino-terminal frameshift mutations result in premature stop codons that allow for translation of proteins that are compromised in their transcriptional activation function. In addition, in-frame mutations between the carboxyterminal basic region and the leucine zipper motif result in proteins with impaired DNA binding activity. The presence of either mutation in the background of a wildtype FLT3 gene likely confers a favorable prognosis in patients undergoing chemotherapy alone. 53 
Impact of Biologic Markers in Planning Therapy
Because most adult patients with AML are not cured, the NCCN Clinical Practice Guidelines in Oncology: Acute Myeloid Leukemia (in this issue; to view the most recent version, visit the NCCN Web site at www.nccn.org) continue to recommend participation in clinical trials to improve outcomes. 54 However, the recognition that certain risk factors define distinct subgroups has facilitated the development of risk-adapted therapy for this disease. Treatment is guided by host and disease characteristics, and therefore a hierarchical approach to treatment planning can be envisioned.
On the simplest level, age and patient history are the first important pieces of information readily available. The very elderly (≥ 75 years) may not be offered standard therapy but instead directed to a tertiary care center with an active clinical research program. Because patients with secondary AML are unlikely to be cured with standard induction and consolidation alone, investigational approaches including some form of stem cell transplantation may be considered from the onset.
Morphologic review of blood and bone marrow remains the mainstay of diagnosis and also represents an important step in recognizing AML subtypes. Various syndromes of AML are first appreciated by their morphology. The standard variety of hypergranular APL is readily recognizable and ATRA-based therapy is often initiated after the bone marrow morphology is examined. Subsequently, the diagnosis may be confirmed through cytogenetics and molecular analysis. In addition, polymerase chain reaction (PCR) for the PML/RAR transcript ␣ serves as a sensitive and clinically useful method to monitor the status of remission and detect minimal residual disease.
15
A similar paradigm may exist for the core-factor binding leukemia syndromes. The t(8;21) translocation is more prevalent among morphologic AML with differentiation. 55 Also, immunophenotyping with the expression of a cross-lineage marker such as CD19 or CD2 provide another clue to the underlying genetic abnormality. The inv(16) and t(16;16) translocations are usually found among the myelomonocytic leukemias, and morphologically have characteristic abnormal eosinophils that contain large basophilic granules. 56 Unlike APL, however, these disorders are treated with standard induction. Traditional karyotyping confirms the cytogenetic diagnosis and helps in planning postremission therapy, which usually involves multiple courses of high-dose Ara-C.
For most patients, however, morphology and immunophenotyping are not predictive of underlying cytogenetics, and karyotype information becomes available only after chemotherapy has commenced. Therefore, the clinical significance of this data generally becomes important in planning postremission therapy. Patients subsequently found to have a poorrisk karyotype after remission induction are more likely referred to undergo some variation of stem cell transplantation. The good-risk group would not require stem cell transplantation in first CR, but instead would receive high-dose chemotherapy alone.
Patients with normal cytogenetics previously presented a challenge for clinicians, because outcomes vary widely and no other prognostic data existed. The data now available from molecular/genetic studies allows for further stratification based on these risk factors. Testing for FLT3 gene mutations, BAALC overexpression, PTD of MLL, WT1 mutations, and overexpression of ERG and MN1 is important because of the negative impact on patient outcomes, and therefore may gradually be incorporated into the standard workup for AML and used to individualize patient therapy. [57] [58] [59] For example, 3 small molecule inhibitors of FLT3 (MLN518, PKC412, and CEP-701) have recently been shown to have biologic activity in phase I trials in patients with documented ITD mutations. [60] [61] [62] [63] Mutation of genes such as CEBP␣ and NPM1 are generally associated with a favorable prognosis, and testing will be important in defining biologic subtypes that require less therapy. The presence of some of these mutations may modify the effect of others, so the establishment of a panel of significant markers may be needed to adequately assess risk and plan care.
A series of recent studies have used gene expression and microRNA profiling to better understand the gene expression alterations and molecular variation that underlie the clinical heterogeneity of both normal cytogenetic AML and AML associated with specific reciprocal translocations. 59, [64] [65] [66] [67] [68] [69] [70] [71] [72] Ultimately, the goal of these studies is to identify a common set of genes whose gene expression signature could accurately predict not only response to therapy but also long-term survival.
The challenge for molecular/genetic testing as a supplement to cytogenetic analysis is validating the biologic subgroups in terms of treatment outcomes and formulating standard risk-adapted therapies for each group. In addition, transitioning this testing from the research laboratory to the clinical laboratory may be problematic for some markers involved. The experience in chronic myelogenous leukemia with regard to quantitative PCR for the BCR-ABL transcript is instructive in this regard. 73 Molecular testing must be standardized so that data can be interpreted independent of the institution providing the results and clinicians can use a common language in planning therapy for patients. 
